Search

Your search keyword '"Vavricka, Stephan R."' showing total 641 results
Start Over Author "Vavricka, Stephan R." Publication Type Academic Journals
641 results on '"Vavricka, Stephan R."'

4. Corrigendum: NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22

Author

Spalinger, Marianne R., Kasper, Stephanie, Gottier, Claudia, Lang, Silvia, Atrott, Kirstin, Vavricka, Stephan R., Scharl, Sylvie, Gutte, Petrus M., Grutter, Markus G., Beer, Hans-Dietmar, Contassot, Emmanuel, Chan, Andrew C., Dai, Xuezhi, Rawlings, David J., Mair, Florian, Becher, Burkhard, Falk, Werner, Fried, Michael, Rogler, Gerhard, and Scharl, Michael

Subjects
Health care industry
Abstract

Original citation: J Clin Invest. 2016;126(5):1783-1800. https://doi.org/10.1172/JCI83669. https://doi.org/10.1172/JCI169304 The authors recently became aware of errors in Figure 8, A and B. In Figure 8A, the WT/[H.sub.2]O and WT/DSS pictures were [...]

Published
2023
Full Text
View/download PDF

5. Alcohol and cannabis consumption in patients with inflammatory bowel disease: prevalence, pattern of consumption and impact on the disease

Author

Martinho-Grueber, Maude, Kapoglou, Ioannis, Bravo, Francisco, Sarraj, Riad, Benz, Eileen, Restellini, Sophie, Biedermann, Luc, Rogler, Gerhard, Vavricka, Stephan R., Schoepfer, Alain, Maillard, Michel H., Michetti, Pierre, Brunner, Felix, Clair, Carole, Barry, Mamadou Pathe, Pittet, Valérie, von Känel, Roland, and Juillerat, Pascal

Published
2023
Full Text
View/download PDF

7. Impact of Overweight and Obesity on Disease Outcome in the Pediatric Swiss Inflammatory Bowel Disease Cohort

Author

von Graffenried, Thea, Schoepfer, Alain M., Rossel, Jean-Benoit, Greuter, Thomas, Safroneeva, Ekaterina, Godat, Sébastien, Henchoz, Sarah, Vavricka, Stephan R., Sokollik, Christiane, Spalinger, Johannes, Braegger, Christian P., Nydegger, Andreas, Abdelrahman, Karim, Ademi, Gentiana, Aepli, Patrick, Thomas, Amman, Anderegg, Claudia, Antonino, Anca-Teodora, Archanioti, Eva, Arrigoni, Eviano, de Jong, Diana Bakker, Balsiger, Bruno, Bastürk, Polat, Bauerfeind, Peter, Becocci, Andrea, Belli, Dominique, Bengoa, José M., Biedermann, Luc, Binek, Janek, Blattmann, Mirjam, Boehm, Stephan, Boldanova, Tujana, Borovicka, Jan, Braegger, Christian P., Brand, Stephan, Brügger, Lukas, Brunner, Simon, Bühr, Patrick, Burnand, Bernard, Burk, Sabine, Burri, Emanuel, Buyse, Sophie, Cao, Dahlia-Thao, Carstens, Ove, Criblez, Dominique H., Cunningham, Sophie, D’Angelo, Fabrizia, de Saussure, Philippe, Degen, Lukas, Delarive, Joakim, Doerig, Christopher, Dora, Barbara, Drerup, Susan, Egger, Mara, El-Wafa, Ali, Engelmann, Matthias, Felley, Christian, Fliegner, Markus, Fournier, Nicolas, Fraga, Montserrat, Franc, Yannick, Frei, Pascal, Frei, Remus, Fried, Michael, Froehlich, Florian, Furlano, Raoul Ivano, Garzoni, Luca, Geyer, Martin, Girard, Laurent, Girardin, Marc, Golay, Delphine, Good, Ignaz, Bigler, Ulrike Graf, Gysi, Beat, Haarer, Johannes, Halama, Marcel, Haldemann, Janine, Heer, Pius, Heimgartner, Benjamin, Helbling, Beat, Hengstler, Peter, Herzog, Denise, Hess, Cyrill, Heyland, Klaas, Hinterleitner, Thomas, Hirschi, Claudia, Hruz, Petr, Juillerat, Pascal, Khalid-de Bakker, Carolina, Kayser, Stephan, Keller, Céline, Knellwolf, Christina, Knoblauch, Christoph, Köhler, Henrik, Koller, Rebekka, Krieger, Claudia, Künzler, Patrizia, Kusche, Rachel, Lehmann, Frank Serge, Macpherson, Andrew, Maillard, Michel H., Manz, Michael, Marot, Astrid, Meier, Rémy, Meyenberger, Christa, Meyer, Pamela, Michetti, Pierre, Misselwitz, Benjamin, Mosler, Patrick, Mottet, Christian, Müller, Christoph, Müllhaupt, Beat, Musso, Leilla, Neagu, Michaela, Nichita, Cristina, Niess, Jan, Nydegger, Andreas, Obialo, Nicole, Ollo, Diana, Oropesa, Cassandra, Peter, Ulrich, Peternac, Daniel, Petit, Laetitia Marie, Pittet, Valérie, Pohl, Daniel, Porzner, Marc, Preissler, Claudia, Raschle, Nadia, Rentsch, Ronald, Restellini, Alexandre, Restellini, Sophie, Richterich, Jean-Pierre, Ris, Frederic, Risti, Branislav, Ritz, Marc Alain, Rogler, Gerhard, Röhrich, Nina, Rossel, Jean-Benoît, Rueger, Vanessa, Rusticeanu, Monica, Sagmeister, Markus, Saner, Gaby, Sauter, Bernhard, Sawatzki, Mikael, Scharl, Michael, Schelling, Martin, Schibli, Susanne, Schlauri, Hugo, Schluckebier, Dominique, Schmid, Daniela, Schmid, Sybille, Schnegg, Jean-François, Schoepfer, Alain, Seematter, Vivianne, Seibold, Frank, Seirafi, Mariam, Semadeni, Gian-Marco, Senning, Arne, Sokollik, Christiane, Sommer, Joachim, Spalinger, Johannes, Spangenberger, Holger, Stadler, Philippe, Staub, Peter, Staudenmann, Dominic, Stenz, Volker, Steuerwald, Michael, Straumann, Alex, Stulz, Andreas, Sulz, Michael, Tatu, Aurora, Tempia-Caliera, Michela, Thorens, Joël, Truninger, Kaspar, Tutuian, Radu, Urfer, Patrick, Vavricka, Stephan, Viani, Francesco, Vögtlin, Jürg, Von Känel, Roland, Vouillamoz, Dominique, Vulliamy, Rachel, Wiesel, Paul, Wiest, Reiner, Wöhrle, Stefanie, Zamora, Samuel, Zander, Silvan, Zeitz, Jonas, and Zimmermann, Dorothee

Published
2022
Full Text
View/download PDF

8. Abdominal pain in patients with inflammatory bowel disease: association with single-nucleotide polymorphisms prevalent in irritable bowel syndrome and clinical management

Author

Ledergerber, Martina, Lang, Brian M., Heinrich, Henriette, Biedermann, Luc, Begré, Stefan, Zeitz, Jonas, Krupka, Niklas, Rickenbacher, Andreas, Turina, Matthias, Greuter, Thomas, Schreiner, Philipp, Roth, René, Siebenhüner, Alexander, Vavricka, Stephan R., Rogler, Gerhard, Beerenwinkel, Niko, and Misselwitz, Benjamin

Published
2021
Full Text
View/download PDF

14. Histological Phenotyping in Eosinophilic Esophagitis: Localized Proximal Disease Is Infrequent but Associated with Less Severe Disease and Better Disease Outcome.

Author

Heil, Alexis, Kuehlewindt, Tobias, Godat, Anne, Simon, Hans-Uwe, Simon, Dagmar, Schreiner, Philipp, Saner, Catherine, Vavricka, Stephan R., Biedermann, Luc, Safroneeva, Ekaterina, Rossel, Jean-Benoit, Limacher, Andreas, Straumann, Alex, Schoepfer, Alain M., and Greuter, Thomas

Subjects
EOSINOPHILIC esophagitis, GASTROESOPHAGEAL reflux, SYMPTOMS, TREATMENT failure, EOSINOPHILIA, REGRESSION analysis
Abstract

Introduction: It is still unknown whether eosinophilic esophagitis (EoE) patients with localized disease are different from those with extended disease. Methods: We evaluated prospectively included patients in the Swiss EoE cohort. Data on all patients with active disease at baseline, no concomitant gastroesophageal reflux disease, no strictures at baseline, and at least one follow-up visit were analyzed. We compared patients with histologically localized proximal versus distal versus extended (=proximal and distal) disease with regard to patient, disease characteristics, disease presentation, and development of complications. Results: We included 124 patients with a median of 2.5 years of follow-up (73.4% males, median age 35.0 years). Ten patients had proximal (8.1%), 46 patients had distal (37.1%), and 68 patients had extended disease (54.8%). Patients with proximal disease were significantly more often females (80%) compared with patients with distal (26.1%, p = 0.002) or extended disease (19.1%, p < 0.001) and reported less severe symptoms (VAS 0 vs. VAS 1, p = 0.001). Endoscopic and histological disease was less pronounced in the proximal esophagus of proximal EoE compared to extended disease (EREFS 1.0 vs. 3.0, p = 0.001; 27.0 eos/hpf vs. 52.5 eos/hpf, p = 0.008). Patients with proximal disease were less likely to undergo dilation compared to patients with distal disease in the follow-up (3.3% vs. 23.3%, p = 0.010). In a multivariate Cox regression model, proximal eosinophilia was less likely to be associated with treatment failure compared to distal eosinophilia. Conclusion: Although isolated proximal EoE is infrequent, it is associated with less severe disease and better disease outcome. Proximal disease appears to present a unique EoE phenotype. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. The Relevance of Vitamin and Iron Deficiency in Patients with Inflammatory Bowel Diseases in Patients of the Swiss IBD Cohort

Author

Madanchi, Matiar, Fagagnini, Stefania, Fournier, Nicolas, Biedermann, Luc, Zeitz, Jonas, Battegay, Edouard, Zimmerli, Lukas, Vavricka, Stephan R, Rogler, Gerhard, Scharl, Michael, Anderegg, Claudia, Bauerfeind, Peter, Beglinger, Christoph, Begré, Stefan, Belli, Dominique, Bengoa, José M, Biedermann, Luc, Bigler, Beat, Binek, Janek, Blattmann, Mirjam, Boehm, Stephan, Borovicka, Jan, Braegger, Christian P, Brunner, Nora, Bühr, Patrick, Burnand, Bernard, Burri, Emanuel, Buyse, Sophie, Cremer, Matthias, Criblez, Dominique H, Saussure, Philippe de, Degen, Lukas, Delarive, Joakim, Doerig, Christopher, Dora, Barbara, Dorta, Gian, Egger, Mara, Ehmann, Tobias, El-Wafa, Ali, Engelmann, Matthias, Ezri, Jessica, Felley, Christian, Fliegner, Markus, Fournier, Nicolas, Fraga, Montserrat, Frei, Pascal, Frei, Remus, Fried, Michael, Froehlich, Florian, Funk, Christian, Furlano, Raoul Ivano, Gallot-Lavallée, Suzanne, Geyer, Martin, Girardin, Marc, Golay, Delphine, Grandinetti, Tanja, Gysi, Beat, Haack, Horst, Haarer, Johannes, Helbling, Beat, Hengstler, Peter, Herzog, Denise, Hess, Cyrill, Heyland, Klaas, Hinterleitner, Thomas, Hiroz, Philippe, Hirschi, Claudia, Hruz, Petr, Iwata, Rika, Jost, Res, Juillerat, Pascal, Brondolo, Vera Kessler, Knellwolf, Christina, Knoblauch, Christoph, Köhler, Henrik, Koller, Rebekka, Krieger-Grübel, Claudia, Kullak-Ublick, Gerd, Künzler, Patrizia, Landolt, Markus, Lange, Rupprecht, Lehmann, Frank Serge, Macpherson, Andrew, Maerten, Philippe, Maillard, Michel H, Manser, Christine, Manz, Michael, Marbet, Urs, Marx, George, Matter, Christoph, McLin, Valérie, Meier, Rémy, Mendanova, Martina, Meyenberger, Christa, Michetti, Pierre, Misselwitz, Benjamin, Moradpour, Darius, Morell, Bernhard, Mosler, Patrick, Mottet, Christian, Müller, Christoph, Müller, Pascal, Müllhaupt, Beat, Münger-Beyeler, Claudia, Musso, Leilla, Nagy, Andreas, Neagu, Michaela, Nichita, Cristina, Niess, Jan, Noël, Natacha, Nydegger, Andreas, Obialo, Nicole, Oneta, Carl, Oropesa, Cassandra, Peter, Ueli, Peternac, Daniel, Petit, Laetitia Marie, Piccoli-Gfeller, Franziska, Pilz, Julia Beatrice, Pittet, Valérie, Raschle, Nadia, Rentsch, Ronald, Restellini, Sophie, Richterich, Jean-Pierre, Rihs, Sylvia, Ritz, Marc Alain, Roduit, Jocelyn, Rogler, Daniela, Rogler, Gerhard, Rossel, Jean-Benoît, Sagmeister, Markus, Saner, Gaby, Sauter, Bernhard, Sawatzki, Mikael, Schäppi, Michela, Scharl, Michael, Schelling, Martin, Schibli, Susanne, Schlauri, Hugo, Uebelhart, Sybille Schmid, Schnegg, Jean-François, Schoepfer, Alain, Seibold, Frank, Seirafi, Mariam, Semadeni, Gian-Marco, Semela, David, Senning, Arne, Sidler, Marc, Sokollik, Christiane, Spalinger, Johannes, Spangenberger, Holger, Stadler, Philippe, Steuerwald, Michael, Straumann, Alex, Straumann-Funk, Bigna, Sulz, Michael, Thorens, Joël, Tiedemann, Sarah, Tutuian, Radu, Vavricka, Stephan, Viani, Francesco, Vögtlin, Jürg, Känel, Roland Von, Vonlaufen, Alain, Vouillamoz, Dominique, Vulliamy, Rachel, Wermuth, Jürg, Werner, Helene, Wiesel, Paul, Wiest, Reiner, Wylie, Tina, Zeitz, Jonas, and Zimmermann, Dorothee

Published
2018
Full Text
View/download PDF

28. Because I'm happy – positive affect and its predictive value for future disease activity in patients with inflammatory bowel diseases: a retrospective cohort study.

Author

Lang, Brian M., Ledergerber, Martina, Jordi, Sebastian Bruno Ulrich, Krupka, Niklas, Biedermann, Luc, Schreiner, Philipp, Juillerat, Pascal, Wyss, Jacqueline, Vavricka, Stephan R., Zeitz, Jonas, von Känel, Roland, Rogler, Gerhard, Beerenwinkel, Niko, and Misselwitz, Benjamin

Subjects
AFFECT (Psychology), INFLAMMATORY bowel diseases, PROPORTIONAL hazards models, COHORT analysis
Abstract

Background: While the detrimental impact of negative emotions on the clinical course of inflammatory bowel disease (IBD) and quality of life has been extensively investigated, evidence for a potential impact of positive emotions is scarce. Objectives: We aim to analyse contributing factors of positive affect and their predictive value for disease course in IBD patients. Design: In this retrospective cohort study, epidemiological, psychosocial and IBD disease characteristics of Swiss IBD cohort study patients were analysed longitudinally. Methods: Epidemiological, psychosocial and disease characteristics were extracted from the database of the Swiss IBD cohort study. Participants' positive emotions were assessed cross-sectionally with the seven-item Marburg questionnaire (range 1–6) addressing positive affect in different aspects of daily life. Predictors of positive emotions were identified by linear regression. The quantitative longitudinal impact of positive emotions on the further disease course was analysed using a multivariable Cox proportional hazards model. Results: Among 702 IBD patients, those reporting more positive emotions were found to have significantly less intense medical treatment, less pain and fewer depressive symptoms (p < 0.05). A higher percentage of variability in positive emotions was explained by pain (36%) and depressive symptoms (13%) than by epidemiological characteristics (0.3%), or characteristics of IBD and its treatment (2.4%). Patients with higher levels of positive emotions (score > 3.5) experienced longer flare-free survival, also after adjusting for confounders (adjusted hazard ratio: 0.39, p < 0.05). Conclusions: The absence of pain and depressive symptoms were the strongest drivers for high positive affect. Higher scores of positive affect were associated with longer disease-free survival in IBD patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

29. NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22

Author

Spalinger, Marianne R., Kasper, Stephanie, Gottier, Claudia, Lang, Silvia, Atrott, Kirstin, Vavricka, Stephan R., Scharl, Sylvie, Gutte, Petrus M., Grutter, Markus G., Beer, Hans-Dietmar, Contassot, Emmanuel, Chan, Andrew C., Dai, Xuezhi, Rawlings, David J., Mair, Florian, Becher, Burkhard, Falk, Werner, Fried, Michael, Rogler, Gerhard, and Scharl, Michael

Subjects
Tyrosine -- Research, Phosphorylation -- Analysis, Health care industry
Abstract

Inflammasomes form as the result of the intracellular presence of danger-associated molecular patterns and mediate the release of active IL-1β, which influences a variety of inflammatory responses. Excessive inflammasome activation results in severe inflammatory conditions, but physiological IL-1β secretion is necessary for intestinal homeostasis. Here, we have described a mechanism of NLRP3 inflammasome regulation by tyrosine phosphorylation of NLRP3 at Tyr861. We demonstrated that protein tyrosine phosphatase non-receptor 22 (PTPN22), variants in which are associated with chronic inflammatory disorders, dephosphorylates NLRP3 upon inflammasome induction, allowing efficient NLRP3 activation and subsequent IL-1β release. In murine models, PTPN22 deficiency resulted in pronounced colitis, increased NLRP3 phosphorylation, but reduced levels of mature IL-1β. Conversely, patients with inflammatory bowel disease (IBD) that carried an autoimmunity-associated PTPN22 variant had increased IL-1β levels. Together, our results identify tyrosine phosphorylation as an important regulatory mechanism for NLRP3 that prevents aberrant inflammasome activation., Introduction Inflammasomes are large, multiprotein complexes that form upon cytosolic or nuclear presence of damage- or pathogen-associated molecular patterns, ultimately leading to the secretion of IL-1β and IL-18. Inflammasomes consist [...]

Published
2016
Full Text
View/download PDF

32. 1178 PROMISING EFFICACY OF SMALL MOLECULES AND BIOLOGICALS FOR MICROSCOPIC COLITIS: RESULTS FROM A LARGE REAL-LIFE MULTICENTER COHORT

Author

Verstockt, Bram, Taelman, Thibault, Vavricka, Stephan R., Zabana, Yamile, Lenfant, Matthias, Macaigne, Gilles, Maillard, Michel H., Savarino, Edoardo, Teich, Niels, Kiudelis, Vytautas, De La Revilla Negro, Juan, Ribaldone, Davide Giuseppe, Barreiro-De-Acosta, Manuel, Wildt, Signe, Rivière, Pauline, Fumery, Mathurin, Truyens, Marie, Amiot, Aurelien, Marsal, Jan, Levartovsky, Asaf, Vieujean, Sophie, Somers, Michaël, Cremer, Anneline, Lyutakov, Ivan, Cohen, Nathaniel A., De Wit, Sophie, Bajer, Lukas, Rahier, Jean-Francois, Backman, Ann-Sofie, Nancey, Stephane, Choden, Tenzin, Van Dongen, Jurgen, Munch, Andreas, and Julsgaard, Mette

Published
2024
Full Text
View/download PDF

35. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations

Author

Gionchetti, Paolo, Dignass, Axel, Danese, Silvio, Magro Dias, Fernando José, Rogler, Gerhard, Lakatos, Péter Laszlo, Adamina, Michel, Ardizzone, Sandro, Buskens, Christianne J., Sebastian, Shaji, Laureti, Silvio, Sampietro, Gianluca M., Vucelic, Boris, van der Woude, C. Janneke, Barreiro-de Acosta, Manuel, Maaser, Christian, Portela, Francisco, Vavricka, Stephan R., and Gomollón, Fernando

Published
2017
Full Text
View/download PDF

37. Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease–a Case Series.

Author

Vieujean, Sophie, Moens, Annick, Hassid, Deborah, Rothfuss, Katja, Savarino, Edoardo Vincenzo, Vavricka, Stephan R, Reenaers, Catherine, Jacobsen, Bent Ascanius, Allez, Matthieu, Ferrante, Marc, and Rahier, Jean-Francois

Abstract

Background and Aim Pneumocystis jirovecii pneumonia [PJP] is a very rare, potentially life-threatening pulmonary fungal infection that occurs in immunocompromised individuals including patients with inflammatory bowel disease [IBD]. Our aim was to describe immunosuppressive treatment exposure as well as the outcome in IBD patients with PJP. Methods PJP cases were retrospectively collected through the COllaborative Network For Exceptionally Rare case reports of the European Crohn's and Colitis Organisation. Clinical data were provided through a case report form. Results In all, 18 PJP episodes were reported in 17 IBD patients [10 ulcerative colitis and seven Crohn's disease]. The median age at PJP diagnosis was 55 years (interquartile range [IQR], 40–68 years]. Two PJP [11.1%] occurred in patients on triple immunosuppression, 10 patients [55.6%] had double immunosuppressive treatment, four patients [22.2%] had monotherapy and two PJP occurred in absence of immunosuppressive treatment [one in a human immunodeficiency virus patient and one in a patient with a history of autologous stem cell transplantation]. Immunosuppressive therapies included steroids [ n  = 12], thiopurines [ n  = 10], infliximab [ n  = 4], ciclosporin [ n  = 2], methotrexate [ n  = 1], and tacrolimus [ n  = 1]. None of the patients diagnosed with PJP had received prophylaxis. All patients were treated by trimethoprim/sulphamethoxazole or atovaquone and an intensive care unit [ICU] stay was required in seven cases. Two patients [aged 71 and 32 years] died, and one patient had a recurrent episode 16 months after initial treatment. Evolution was favourable for the others. Conclusion This case series reporting potentially fatal PJP highlights the need for adjusted prophylactic therapy in patients with IBD on immunosuppressive therapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

38. Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn's Disease: A Multi-Center Retrospective Cohort Study.

Author

Albshesh, Ahmad, Bannon, Lian, Sharar Fischler, Tali, Truyens, Marie, Vavricka, Stephan R., Tepes, Katja, Pugliese, Daniela, Savarino, Edoardo V., Zittan, Eran, Drobne, David, Roblin, Xavier, Bar-Gil Shitrit, Ariella, Armuzzi, Alessandro, Lobaton, Triana, Maharshak, Nitsan, Yanai, Henit, Ben-Horin, Shomron, and Kopylov, Uri

Subjects
CROHN'S disease, VEDOLIZUMAB, DISEASE remission, COHORT analysis, BIOTHERAPY
Abstract

Background: The effectiveness of anti-TNF or ustekinumab (UST) as a second-line biologic after vedolizumab (VDZ) failure has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, We aim to investigate the effectiveness of anti-TNF and UST as second-line therapy in patients with Crohn's disease (CD) who failed VDZ as a first-line treatment. The primary outcome was clinical response at week 16–22. Secondary outcomes included the rates of clinical remission, steroid-free clinical remission, CRP normalization, and adverse events. Results: Fifty-nine patients who failed on VDZ as a first-line treatment for CD were included; 52.8% patients received anti-TNF and 47.2% UST as a second-line therapy. In initial period (Week 16–22), the clinical response and remission rate was similar between both groups: 61.2% vs. 68%, p = 0.8 and 48.3% vs. 56%, p = 0.8 on anti-TNF and UST therapy, respectively. Furthermore, in the maintenance period the rate was similar: 75% vs. 82.3%, p = 0.8 and 62.5% vs. 70.5%, p = 0.8, respectively. Of the patients, 12 out of the 59 stopped the therapy, without a significant difference between the two groups (p = 0.6). Conclusion: Second-line biological therapy after VDZ failure therapy was effective in >60% of the patients with CD. No differences in effectiveness were detected between the use of anti-TNF and UST as a second line. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

43. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease

Author

Harbord, Marcus, Annese, Vito, Vavricka, Stephan R., Allez, Matthieu, Barreiro-de Acosta, Manuel, Boberg, Kirsten Muri, Burisch, Johan, De Vos, Martine, De Vries, Anne-Marie, Dick, Andrew D., Juillerat, Pascal, Karlsen, Tom H., Koutroubakis, Ioannis, Lakatos, Peter L., Orchard, Tim, Papay, Pavol, Raine, Tim, Reinshagen, Max, Thaci, Diamant, Tilg, Herbert, and Carbonnel, Franck

Published
2016
Full Text
View/download PDF

46. Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients

Author

Safroneeva, E., Vavricka, S., Fournier, N., Seibold, F., Mottet, C., Nydegger, A., Ezri, J., Straumann, A., Rogler, G., Schoepfer, A. M., Bauerfeind, Peter, Beglinger, Christoph, Begré, Stefan, Bengoa, José, Binek, Janek, Boller, Daniel, Borovicka, Jan, Braegger, Christian, Burnand, Bernard, Camara, Rafael, Criblez, Dominique, de Saussure, Philippe, Degen, Lukas, Delarive, Joakim, Ehmann, Tobias, Engelmann, Matthias, Wafa, Ali El, Felley, Christian, Frei, Alain, Frei, Pascal, Frei, Remus, Fried, Michael, Froehlich, Florian, Gallot-Lavallée, Suzanne, Gerlach, Tilman, Geyer, Martin, Girardin, Marc, Goetze, Oliver, Haack, Horst, Hediger, Serge, Hengstler, Peter, Heyland, Klaas, Janiak, Patrick, Juillerat, Pascal, Brondolo, Vera Kessler, Knoblauch, Christoph, Kullak-Ublick, Gerd A., Maillard, Michel, Manser, Christine, Marbet, Urs, Manz, Michael, Meier, Rémy, Meyenberger, Christa, Michetti, Pierre, Mottet, Christian, Müller, Christoph, Müllhaupt, Beat, Nicolet, Thierry, Nydegger, Andreas, Piccoli, Franziska, Pilz, Julia, Pittet, Valérie, Rentsch, Ronald, Rey, Jean-Pierre, Rogler, Daniela, Rogler, Gerhard, Sagmeister, Markus, Sauter, Bernhard, Schaub, Niklaus, Schibli, Susanne, Schoepfer, Alain M., Seibold, Frank, Spalinger, Johannes, Stadler, Philippe, Steuerwald, Michael, Straumann, Alex, Sulz, Michael, Thorens, Joël, Vader, John-Paul, Vavricka, Stephan R., Vögtlin, Jürg, Von Känel, Roland, Wachter, Gert, Wermuth, Jürg, and Wiesel, Paul

Published
2015
Full Text
View/download PDF

47. Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study.

Author

Vavricka, Stephan R., Greuter, Thomas, Cohen, Benjamin L., Reinisch, Walter, Steinwurz, Flavio, Fellmann, Marc, Guo, Xiang, Lawendy, Nervin, Paulissen, Jerome, and Peyrin-Biroulet, Laurent

Subjects
*TREATMENT effectiveness, *PATIENT safety, *ULCERATIVE colitis, *KINASE inhibitors, *SMALL molecules
Abstract

Background: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Here, we report steroid-free efficacy and safety with tofacitinib among patients with UC who received corticosteroids at baseline of the maintenance study (OCTAVE Sustain). Methods: This analysis included patients with clinical response following OCTAVE Induction 1 and 2 who were re-randomized to receive placebo, or tofacitinib 5 or 10 mg twice daily (b.d.), in OCTAVE Sustain for 52 weeks and were receiving corticosteroids at OCTAVE Sustain baseline. Corticosteroid tapering was mandatory during OCTAVE Sustain. Rates of steroid-free remission, endoscopic improvement, and clinical response were assessed, stratified by baseline characteristics. Adverse events (AEs) were stratified by treatment and steroid-free remission status. Results: Overall, 289/593 patients had corticosteroid use at OCTAVE Sustain baseline. At week 52, steroid-free remission, endoscopic improvement, and clinical response rates were 10.9%, 11.9%, and 17.8% among patients receiving placebo, 27.7%, 29.7%, and 40.6% among patients receiving tofacitinib 5 mg b.d., and 27.6%, 29.9%, and 43.7% among patients receiving tofacitinib 10 mg b.d., respectively (non-responder imputation; all p < 0.05 tofacitinib 5 or 10 mg b.d. versus placebo). Discontinuations due to AEs were lower among patients with steroid-free remission versus without. AEs of special interest were infrequent. Conclusion: For patients with baseline corticosteroid use in OCTAVE Sustain, the odds of achieving steroid-free efficacy endpoints were significantly higher for tofacitinib versus placebo, irrespective of tofacitinib dose. There were no apparent differences in AEs of special interest by steroid-free remission status. ClinicalTrials.gov: NCT01458574 [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

48. Sa1280 HISTOLOGICAL PHENOTYPING IN EOSINOPHILIC ESOPHAGITIS: LOCALIZED PROXIMAL DISEASE IS INFREQUENT, BUT ASSOCIATED WITH LESS SEVERE DISEASE AND BETTER DISEASE OUTCOME

Author

Heil, Alexis, Kuehlewindt, Tobias, Godat, Anne, Simon, Hans-Uwe, Simon, Dagmar, Schreiner, Philipp, Saner, Catherine, Vavricka, Stephan R., Biedermann, Luc, Safroneeva, Ekaterina, Rossel, Jean-Benoit, Limacher, Andreas, Straumann, Alex, Schoepfer, Alain M., and Greuter, Thomas

Published
2023
Full Text
View/download PDF

50. fMLP induces Hsp27 expression, attenuates NF-[kappa]B activation, and confers intestinal epithelial cell protection

Author

Carlson, Ryan M., Vavricka, Stephan R., Eloranta, Jyrki J., Musch, Mark W., Arvans, Donna L., Kles, Keri A., Walsh-Reitz, Margaret M., Kullak-Ublick, Gerd A., and Chang, Eugene B.

Subjects
Heat shock proteins -- Research, Epithelial cells -- Research, Actin -- Research, Homeostasis -- Research, Biological sciences
Abstract

Sustained expression of cytoprotective intestinal epithelial heat shock proteins (Hsps), particularly Hsp27, depends on stimuli derived from bacterial flora. In this study, we examined the role of the bacterial chemotactic peptide fMLP in stimulating colonic epithelial Hsp expression at concentrations encountered in a physiological milieu. Treatment of the polarized human intestinal epithelial cell line Caco2bbe with physiological concentrations of fMLP (10-100 nM) induced expression of Hsp27, but not Hsp72, in a time- and concentration-dependent manner. Induction of Hsp27 by fMLP was specific since the fMLP analogs MRP and MLP were not effective. Hsp27 induction by fMLP was blocked by the fMLP-receptor antagonist BOC-FLFLF and was blocked when the dipeptide transporter PepT1, an entry pathway for fMLP, was silenced, fMLP activated both the p38 and ERK1/2 MAP kinase pathways in Caco2bbe cells, but not the SAPK/JNK pathway. The p38 inhibitor SB203580, but not the MEK-1 inhibitor PD98059, blocked Hsp27 induction by fMLP. fMLP treatment inhibited actin depolymerization and decreased transepithelial resistance caused by the oxidant monochloramine, and this inhibition was reversed by silencing Hsp27 expression, fMLP pretreatment also inhibited activation of proinflammatory transcription factor NF-[kappa]B by TNF-[alpha] in Caco2bbe cells, reducing induction of NF-[kappa]B target genes by TNF-[alpha] both in human intestinal biopsies and Caco2bbe cells. In conclusion, fMLP may contribute to the maintenance of intestinal homeostasis by mediating physiological expression of Hsp27, enhancing cellular protection, and negatively regulating the inflammatory response. chemotactic peptides; stress proteins; actin; barrier function; NF-[kappa]B

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results